Weller, M; Wick, W (2014). Neuro-oncology in 2013: improving outcome in newly diagnosed malignant glioma. Nature Reviews. Neurology, 10(2):68-70.
In 2013, two discoveries—that alkylating agent chemotherapy prolongs survival when added to radiotherapy for patients with anaplastic oligodendroglial tumours with 1p19q codeletion, and that bevacizumab prolongs progression-free survival in patients with newly diagnosed glioblastoma—have dominated debate in neuro-oncology. These findings could help to define new standards of care in malignant glioma.
In 2013, two discoveries—that alkylating agent chemotherapy prolongs survival when added to radiotherapy for patients with anaplastic oligodendroglial tumours with 1p19q codeletion, and that bevacizumab prolongs progression-free survival in patients with newly diagnosed glioblastoma—have dominated debate in neuro-oncology. These findings could help to define new standards of care in malignant glioma.
| Item Type: | Journal Article, refereed, further contribution |
|---|---|
| Communities & Collections: | 04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology |
| Dewey Decimal Classification: | 610 Medicine & health |
| Language: | English |
| Date: | 2014 |
| Deposited On: | 28 Apr 2014 09:46 |
| Last Modified: | 24 Sep 2019 20:18 |
| Publisher: | Nature Publishing Group |
| ISSN: | 1759-4758 |
| OA Status: | Green |
| Publisher DOI: | https://doi.org/10.1038/nrneurol.2013.268 |
| PubMed ID: | 24419684 |
Weller, M